Company
Ultimovacs ASA
Headquarters: Oslo, Norway
Employees: 24
Market Cap
kr275.6 Million
NOK as of July 1, 2024
US$25.9 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Stocks & Indices
Ultimovacs ASA has the following listings and related stock indices.
Stock: OSE: ULTI wb_incandescent
Stock: FSX: 7UM wb_incandescent